Eris Lifesciences Limited IPO Message Board (Page 19)

ERIS IPO Subscription Day-3 at 12 noon
QIB : 0.815x
NII : 0.0611x
RII : 2.3292x
Emp: 0.5358x
Overall = 0.8848x

CURRENT SUBSCRIPTION DETAILS,
1      Qualified Institutional Buyers (QIBs)      6893442      6711400      0.97
2      Non Institutional Investors      5170081      3152600      0.61
3      Retail Individual Investors(RIIs)      12063523      42026600      3.48
3      Employees      700000      81600      0.12
      Total      24827046      51972200      2.09

I think its for CDSL

QIB 0.81 , HNI 0.06 and RII 2.30 times subscribed till 11.50am today

IPO experts are silent and confused so they don''t coments.

ERIS GMP 18-22

Request Eagle eye M''am & Septa Sir, to comment & suggest for this IPO..

I am looking forward to apply this counter. But subscription seems lackluster.

Uchit bhai / Cham cho... you may also suggest.

Thanks & Regards,

No risk no game.

Nothing for share subscribers - Average pharma company - future is bright but very very highly overpriced price band that too at the face value just Re.1. there are lot of other fast growing pharma companies share available below Rs. 200. So Avoid Eris. Strongly avoid be smart because promoters has not kept anything for retail investors high price at lowest face value.. this message will again get disappeared from this rating. But I have done my job to guide others. Promoters should think about retail or other investors too. From where investors will earn here? At Re.1 face value eris will be good buy at only 100 so don''t pay Rs.550 more per one rupee face valued share of eris.. if u want pharma there are much more good options available. Control your temptation and be wise

Completely dabba ipo. Bullshit company trying to steal investor money by showing inflated profits

Completely dabba ipo. Bullshit company trying to steal investor money by showing inflated profits

ERIS GMP 21-24

DEAR EAGLEYE

Do you think that we will be able to reach to subscription figure quoted by you earlier in ERIS.

What about the total subscription till now ?

Please share the updates.......

ERIS IPO Subscription Day-3 at 10.50am

QIB 0.815x
HNI 0.0568x
RII 2.179x
Emp 0.5243x
Overall 0.86x

ERIS IPO Subscription Day-3 at 10.50am

QIB 0.82x
HNI 0.05x
RII 2.07x
Emp 0.33x
Overall 0.83x

There was message @ 211 saying ICICI Direct will close the ipo application window at 1:00 pm instead of the earlier 3:00 pm .

I just checked ICICI Direct and it says open till 3:00pm

This is copied from ICICI DIRECT IPO page.

APPLY FOR IPO / FPO

Name      Type      Price Determination      Min. Qty      Price Band/Floor Price (Rs.)      Qty Multiples      Max Retail Value      Start Date      End Date & Time      Action

CENTRAL DEPOSITORY SER INDIA LTD : CDSL      IPO       Bidding      100      145.00 - 149.00      100      200,000.00      19-JUN-2017 10:00:00      21-JUN-2017 15:00      GO

ERIS LIFESCIENCES LTD : ERILIF      IPO       Bidding      24      600.00 - 603.00      24      200,000.00      16-JUN-2017 10:00:00      20-JUN-2017 15:00      GO

From where did 211 get this information??

Please check before posting some information.

No Buyers for ERIS in GMP

Here is the subscription links for BSE & NSE.

http://www.bseindia.com/markets/publicIssues/BSEDemandSchedule_new.aspx?Scripcode=3426

https://www.nseindia.com/products/content/equities/ipos/ipo_current_cdsl.htm

https://www.nseindia.com/products/content/equities/ipos/ipo_current_eris.htm

BE AWARE
Those who want to apply through ICICIDirect, note that you can apply till 1.00pm only & today is last day for subscription.

ICICI Direct have corrected the end time to 3 pm.

Good News

ICICIDirect changed end time to 3.00pm (Also changed for CDSL)

LATEST SUBSCRIPTION FIGURE PLEASE
DEAR EAGLEYE PLEASE HELP WITH SY=UBSCRIPTION FIGURE ATLEAST

HINDU BUSINESS LINE REVIEW:
--------------------------
Eris Lifesciences (IPO): Expensive solution

This India-focussed pharma player, with healthy prospects, is asking for a high price

The initial public offer of Ahmedabad-based specialty pharma company Eris Lifesciences (Eris) is underway. The issue is an offer-for-sale by promoters and other shareholders in the price band of Rs 600-603.The company has charted a strong growth path so far on the back of its focus on lifestyle-related specialised therapeutic areas in the Indian market, a high growth opportunity.

A low base has also helped, with the company just about a decade old. The company’s growth prospects seem bright. Strong balance sheet and expansion through acquisitions and entry into new product categories are positives too. Its India-only business model also offers comfort in the current scenario of many export-oriented pharma firms facing regulatory heat abroad.

Premium valuation
But the offer has been priced at a stiff premium, that factors in all these positives and more. At the upper end of the price band (Rs 600-603), the issue’s valuation (price-to-FY17 earnings) is nearly 34 times — much higher than the S&P BSE Pharma’s valuation of about 26 times.

Even compared with the high valuations of some India-focused pharma MNC subsidiaries (24-32 times), the Eris Lifesciences issue seems pricey. The steep valuation of some of the MNC pharma companies can also be called into question.

While the company has been growing faster than many peers, its pace could moderate as size increases and the base gets bigger. Besides, benchmarking valuations with pricey MNC pharma stocks could be tricky, given the different organisation profiles, brand positioning, and premiums due to delisting possibility incorporated in many MNC stocks. Investors can wait out the primary issue and look for more attractive price points to buy into the stock after its listing.

Strong product suite
Incorporated in 2007, Eris Lifesciences manufactures and sells high-margin branded pharmaceutical products only in India. Unlike many India-based pharma peers, the company does not export to foreign markets. Its focus is the fast growing lifestyle-related therapeutic categories in the country. The product portfolio includes niches in high-growth chronic and acute categories such as cardiovascular, anti-diabetics, vitamins, gastroenterology and anti-infectives.

The company operates mainly through the prescription-led business model, with high focus on specialists and super specialists such as cardiologists, diabetologists, endocrinologists and gastroenterologists. More than three-fourth of the company’s revenue comes from metros and Class 1 towns.

Eris is among the top five companies in India by prescription share. The number of doctors prescribing the company’s products increased to 50,282 in FY17 from 37,842 in FY13. It had 1,500 marketing representatives as of March 2017.

The product portfolio comprised 80 mother brand groups as of March 2017. The chronic category, one of the fastest growing segments in the Indian pharmaceutical market (IPM) due to increasing incidence of lifestyle-related diseases, has driven Eris’s growth.

Withdrawn the application. Subscription is too low and offer price is very high!

@ Ksach

Haha ...Apply, then withdraw, then apply again only to withdraw again, Man, you guys know how to keep the registrars Busy and ''Guessing''..:) ..

But then its the registrars that appear incorrigible to me. Stupid folks, why don''t they provide an option to "Auto Withdraw On The Last Day" to the inve''STARS'' right at the time of investing? Hm...These guys just don''t know the worth of both efforts and the time...

Eris Life sciences IPO
3rd Day : 10:20 AM
QIB - 0.81 times
HNI - 0.034 times
RII - 1.9 times (always in hurry)
Total - 0.8 times

should i go for this IPO or not ?